Vascular Dysfunction in Offspring of Assisted Reproduction Technologies
|ClinicalTrials.gov Identifier: NCT00837642|
Recruitment Status : Unknown
Verified January 2009 by University of Lausanne Hospitals.
Recruitment status was: Recruiting
First Posted : February 5, 2009
Last Update Posted : February 5, 2009
The prevalence of infertility has been estimated at 9% worldwide. The steadily increasing use of assisted reproductive technologies (ART) has allowed millions of infertile couples to have children. These children make up for 1 to 4% of the population in developed countries. ART involves the manipulation of early embryos at a time when they may be particularly vulnerable to external disturbances. In line with this concept, studies in mice suggest that ART alters the activity of enzymes involved in the regulation of metabolic and cardiovascular homeostasis. Alternatively, infertility itself or the drugs used to stimulate ovulation may have adverse effects on the outcome of the offspring. The safety of ART for long-term health is, therefore, of utmost importance. Among the potential long-term consequences of ART, cardiovascular disease may represent an important candidate, but there is no information.
Preliminary data from our group show that, children born after in vitro fertilization (IVF) present systemic and pulmonary vascular dysfunction at high-altitude when compared to age- and sex-matched control subjects.
Therefore, the major goal of our proposal is to test the hypothesis that apparently healthy children born after ART display vascular dysfunction of both the pulmonary and the systemic circulation.
|Condition or disease||Intervention/treatment|
|Infertility||Dietary Supplement: Vitamin C and E|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Vascular Dysfunction in Offspring of Assisted Reproduction Technologies|
|Study Start Date :||March 2008|
|Estimated Primary Completion Date :||April 2009|
|Estimated Study Completion Date :||December 2009|
- Endothelial function
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00837642
|Contact: Urs Scherrer, Prof||+4121 314 09 30||Urs.Scherrer@chuv.ch|
|Contact: Claudio Sartori, Prof||+4121 314 09 30||Claudio.Sartori@chuv.ch|
|Bern, BE, Switzerland, 3000|
|Contact: Yves Allemann, Prof Yves.Allemann@insel.ch|
|Lausanne, VD, Switzerland, 1011|
|Contact: Urs Scherrer, Prof +4121 314 09 30 Urs.Scherrer@chuv.ch|